Zolpidem (Myslee) Post Marketing Study in Adolescent Patients With Insomnia - Evaluation With Polysomnography
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00653562 |
Recruitment Status :
Completed
First Posted : April 7, 2008
Last Update Posted : February 17, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Insomnia Sleep Initiation and Maintenance Disorders | Drug: zolpidem | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 11 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Treatment |
Official Title: | Single Blind, Multi-center, Post Marketing Clinical Study of Zolpidem (Myslee) in Adolescent Patients With Insomnia - Evaluation With Polysomnography |
Study Start Date : | November 2006 |
Actual Primary Completion Date : | March 2010 |
Actual Study Completion Date : | March 2010 |
Arm | Intervention/treatment |
---|---|
Experimental: 1
Patients will receive placebo in one part and zolpidem in the other part
|
Drug: zolpidem
Oral
Other Name: Myslee |
- Sleep latency [ Time Frame: 2 days ]
- Total hours of sleep [ Time Frame: 2 days ]
- Frequency of intermediate awaking [ Time Frame: 2 days ]
- Time of intermediate awaking [ Time Frame: 2 days ]
- Patient impression [ Time Frame: 2 days ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients diagnosed as having nonorganic insomnia of nonorganic sleep disorder in ICD10
Exclusion Criteria:
- Patients with schizophrenia or manic-depressive illness
- Patients with insomnia caused by physical diseases
- Patients having a history of hypersensitivity to zolpidem
- Patients with attention-deficit hyperactivity disorder
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00653562
Japan | |
Kansai, Japan | |
Kantou, Japan | |
Kyusyu, Japan | |
Touhoku, Japan |
Study Chair: | Use Central Contact | Astellas Pharma Inc |
Responsible Party: | Astellas Pharma Inc |
ClinicalTrials.gov Identifier: | NCT00653562 |
Other Study ID Numbers: |
6199-JC-0002 |
First Posted: | April 7, 2008 Key Record Dates |
Last Update Posted: | February 17, 2017 |
Last Verified: | February 2017 |
polysomnography zolpidem Sleep disorders adolescent |
Sleep Initiation and Maintenance Disorders Sleep Disorders, Intrinsic Dyssomnias Sleep Wake Disorders Nervous System Diseases Mental Disorders Zolpidem Sleep Aids, Pharmaceutical |
Hypnotics and Sedatives Central Nervous System Depressants Physiological Effects of Drugs GABA-A Receptor Agonists GABA Agonists GABA Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |